23andMe, a DNA analysis service company who provides information and tools to individuals to learn more about their DNA has announced its plan to invent its own drugs using customer data. This drastic move will allow 23andMe to capitalize on the economic value its genetic databases can create. The company’s robust database has provided genetic information of great value to Pfizer and Genentech, two of the Big Pharma companies.
By focusing on the customer first and foremost, 23andMe plans to develop a new drug that will provide an excellent benefit to its customers. 23andMe, the company that was providing valuable genetic information to two Big Pharma companies may be one of its greatest competitors in the coming years.
Click here to read Matthew Herper’s full article on Forbes.